Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 09/23
43.58 AUD   +3.91%
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals : Strategic Update II - April 2021

04/11/2021 | 07:35pm EDT

C O M P A N Y A N N O U N C E M E N T

Strategic Update II

Expansion of clinical program, products, manufacturing

Melbourne, Australia, 12 April 2021

ASX:

CUV

XETRA-DAX:

UR9

NASDAQ INTERNATIONAL DESIGNATION:

CLVLY

CLINUVEL today announced its second Strategic Update, providing more details on the Group's expansion and growth. The extensive update, a sequel to Strategic Update I (published on 29 October 2020) can be accessed online at https://www.clinuvel.com/strategic-update-ii-intro/.

"Along a continuum of six monthly disclosures, CLINUVEL advanced beyond traditional pharmaceutical reporting by sharing its decision processes and selection criteria, informing its owners of the direction and shape the Company is taking," CLINUVEL's Managing Director Philippe Wolgen said.

"The Strategic Update series additionally aims to inform about the Company's opportunities, and this new format allows us to be more detailed on technology and selected markets. We are progressing towards diversified services and products converging to accretive value as our team achieve the defined objectives."

EXECUTIVE SUMMARY STRATEGIC UPDATE II: Processes, Decisions, Criteria

Commercial

The team achieved the training & accreditation of 40 American Specialty Centers to supply SCENESSE® (afamelanotide 16mg) to EPP patients.

R&D, Clinical Progress

Following two decades of collecting safety data from the human use of systemically administered melanocortins, CLINUVEL is expanding the therapeutic potential of melanocortins and, in particular, SCENESSE® in a number of genetic, metabolic, and life-threatening disorders.

DNA Repair Program

CLINUVEL has uniquely identified several untreated and unserved groups at the highest risk of photodamage and skin cancers, and is developing products and solutions for these populations. Afamelanotide is being evaluated in patients diagnosed with xeroderma pigmentosum C and variant (XP-C and XP-V) with studies to start as soon as COVID restrictions allow in Europe and the United States.

CNS Program - Arterial Ischaemic Stroke

Patients are being screened in the CUV801 trial in Melbourne (AU).

Sixth Indication For Afamelanotide

Outline of the nine selection criteria for the commencement of a new program which is in final stages of preparation.

- Confidential -

Healthcare Solutions

A range of four product lines are in development, with the first OTC product line at its manufacturing stage.

Communications, Branding, Marketing (CBM)

Team 80% recruited to expand the Company's reach and engagement with new audiences.

Manufacturing Division

New division to focus on the development of innovative, controlled-release systemic and topical formulations.

- END -

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life-threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014, the US Food and Drug Administration in 2019 and the Australian Therapeutic Goods Administration in 2020 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA. For more information, please go to http://www.clinuvel.com.

SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, the COVID-19 pandemic affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2020 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com

Page 2 of 3

Strategic Update II

- Confidential -

Level 11

535 Bourke Street

Melbourne - Victoria, Australia, 3000

T +61 3 9660 4900

F +61 3 9660 4999

Page 3 of 3

Strategic Update II

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 12 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 April 2021 23:34:01 UTC.


ę Publicnow 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
09/02CLINUVEL PHARMACEUTICALS LIMITED : Ex-dividend day for final dividend
FA
08/26CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
08/26CLINUVEL PHARMACEUTICALS' : Net Profit Jumps 64% on Higher Drug Demand
MT
08/25CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
08/25CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
08/25CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
08/25Clinuvel Pharmaceuticals Limited Declares Annual Unfranked Dividend for the Year Ending..
CI
More news
Financials
Sales 2022 64,6 M 46,8 M 46,8 M
Net income 2022 30,9 M 22,4 M 22,4 M
Net cash 2022 108 M 78,1 M 78,1 M
P/E ratio 2022 71,5x
Yield 2022 0,10%
Capitalization 2 153 M 1 571 M 1 560 M
EV / Sales 2022 31,7x
EV / Sales 2023 21,9x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 43,58 AUD
Average target price 33,92 AUD
Spread / Average Target -22,2%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED95.25%1 571
CSL LIMITED10.53%104 042
WUXI BIOLOGICS (CAYMAN) INC.17.22%65 634
SAMSUNG BIOLOGICS CO.,LTD.11.38%51 879
BIOGEN INC.18.16%43 697
ALEXION PHARMACEUTICALS, INC.0.00%40 336